Moderna said Monday that its combination vaccine against flu and COVID-19 drew a greater immune response in late-stage study results than two comparable vaccines on the market. The company's ...
Moderna’s combined mRNA-based vaccine for COVID-19 and seasonal influenza ... compared to current flu vaccines, matching GSK’s Fluarix Quadrivalent in adults aged 50 to 64 and outperforming ...
A second group of adults aged 50 to 64 received mRNA-1083 or GSK’s influenza vaccine Fluarix, once again given alongside Spikevax. mRNA-1083 consists of components of mRNA-1010, Moderna’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback